Passive immunotherapies include anti-HER2 targeted monoclonal antibodies, such as trastuzumab, pertuzumab, and margetuximab; whereas active immunotherapies mainly encompass cancer vaccines to boost the antitumor response by activating autologous immune cells and inducing a therapeutic effect [37]. Here, ERBB2 is linked to cancer.